HRSV (A) Post-fusion glycoprotein F0

$465.00 50ug

$3170.00 500ug

Min. Order50ug
Purity>95% as determined by SDS-PAGE.
Cas No
Supply AbilitySubject to availability
Update time2026-04-29

ACROBiosystems

VIP1Y

China

Since:2010-07-22

Address:4th Floor, Building 4, No. 8 Hongda North Road, Beijing Economic-Technological Development Area (BDA

show less show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Manufacturer

Chemical Properties

Product Name	HRSV (A) Post-fusion glycoprotein F0
CAS No
EC-No
Min. Order	50ug
Purity	>95% as determined by SDS-PAGE.
Supply Ability	Subject to availability
Release date	2026/04/29

Synonym
Postfusion glycoprotein F0/post-F protein (RSV)
Source
HRSV (A) Post-fusion glycoprotein F0, His Tag (RSF-V52H6) is expressed from human 293 cells (HEK293).
Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 55.2 kDa. The protein migrates as 47-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Within the expressed region, several mutations were introduced to optimize the protein expression and stability.
The protein is designed as a trimer.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in 0.1 M Sodium citrate, 150 mM NaCl, pH5.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
After reconstitution, this product is stable after storage at -70°C for 3 months.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

For long term storage, the product is stable for up to 3 years at -70°C from date of receipt;
For short term storage, the product is stable for up to 3 months at 2-8°C from date of receipt.

show less show more

Company Profile Introduction

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.